The features of antibacterial therapy in children

2021 ◽  
pp. 52-67
Author(s):  
Lyudmila Yurievna Kulagina ◽  
Albina Ayratovna Zvegintseva ◽  
Alina Garafutdinovna Zamalutdinova ◽  
Maksim Leonidovich Maksimov
Keyword(s):  
Antibiotic Therapy ◽  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Methodological Approach ◽  
Antiviral Effect ◽  
Modern Medicine ◽  
Cost Of Treatment ◽  
Antibacterial Drugs ◽  
The Cost ◽  
Viral Respiratory

At present, the use of antibacterial drugs is one of the most frequently recommended methods of treating a large number of infectious diseases. However, in clinical practice, excessive use of antibiotics, unreasonable antibiotic therapy, and inappropriate combinations are quite common, which creates the risk of unwanted side effects, increases the cost of treatment and leads to an increase in microorganism resistance. That is why, in modern medicine, the problem of rational antibiotic therapy, i.e. the adequate use of antibacterial drugs, compliance with strict indications for their use, certain schemes and principles of use, and the creation of protocols for antibiotic therapy in pediatric practice, remains relevant. Antibacterial drugs should be prescribed for inflammatory diseases of bacterial etiology and for perioperative prophylaxis. Antibiotics should not be used in the treatment of uncomplicated acute viral respiratory diseases, since they do not have an antiviral effect, do not reduce fever, and do not prevent the development of bacterial complications. The purpose of this work is to form a methodological approach to the use of antibacterial drugs in pediatrics based on existing Russian recommendations.

scholarly journals Inhaled antibiotics to improve efficacy and safety in the treatment of upper airway and lung inflammatory diseases

2021 ◽  
pp. 84-92
Author(s):  
Vladimir N. Drozdov ◽  
Konstantin I. Arefev ◽  
Svetlana Y. Serebrova ◽  
Irina A. Komissarenko ◽  
Evgenia V. Shikh ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Targeted Delivery ◽  
Whooping Cough ◽  
Inflammatory Diseases ◽  
Wide Spectrum ◽  
Chronic Obstructive ◽  
Combination Drug ◽  
Antibacterial Drugs ◽  
Systemic Antibiotic Therapy ◽  
Inhaled Antibiotics

Inhaled antibacterial drugs have been used since the 1940s with greater or lesser effectiveness, due to the possibility of targeted delivery of drugs directly to the infection site at concentrations higher than MICs. High local concentrations of antibacterial agents expand the possibilities of treating infections caused by multiresistant strains and reduces antibiotic resistance in the population. The inhaled delivery method is characterized by a high level of safety due to the absence of systemic toxic effects, which reduces the risk of pseudomembranous colitis and other complications of antibiotic therapy. Thiamphenicol glycinate acetylcysteinate is a combined drug that includes thiamphenicol and N-acetylcysteine, which causes its antibacterial and mucolytic activity. The results of clinical studies have demonstrated the effectiveness of TGA in the treatment of acute and chronic bronchitis, chronic obstructive pulmonary disease, community-acquired pneumonia, laryngotracheitis, rhinosinusitis and other infections of the upper and lower respiratory tract. In pediatrics, the drug is used to treat bronchitis and pneumonia, especially those that cannot be treated with other antibacterial drugs, bronchiolitis, whooping cough, and cystic fibrosis. The article presents data on the effectiveness and safety of containing TGA. A wide spectrum of antibacterial actions, the ability to form high local concentrations of antibacterial and mucolytic components in the focus of infection, a low risk of serious side effects in both adults and children are noted. The topical use of the combination drug has proven to be effective not only in bringing about a pronounced clinical improvement, but also in reducing the frequency of use of systemic antibiotic therapy. The efficacy of thiamphenicol glycinate acetylcysteinate is not inferior to macrolide antibiotics.

scholarly journals AMOXYCILLIN FOR COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN

2017 ◽  
pp. 52-55
Author(s):  
A. B. MALAKHOV ◽  
N. G. KOLOSOVA
Keyword(s):  
Respiratory Diseases ◽  
Adverse Reactions ◽  
Bacterial Pathogens ◽  
Community Acquired Pneumonia ◽  
Haemophilus Influenza ◽  
Cost Of Treatment ◽  
Global Challenge ◽  
Beta Hemolytic Streptococcus ◽  
Group A ◽  
The Cost

The majority of respiratory diseases have viral etiology, and they do not require antibacterial therapy since it does not affect the course of the disease, does not reduce the incidence of bacterial complications. The causes of tonsillitis, epiglottitis, pneumonia are bacterial pathogens, such as Streptococcus pyogenes (group A beta-hemolytic streptococcus), Streptococcus pneumoniae,Haemophilus influenza, S. aureus and Moraxella catarrhalis. Home treatment of children remains a global challenge, as it may be the cause of an unfavorable outcome in young children, and, therefore, the issues of diagnostics and rational antibiotic therapy are still relevant. Irrational use of antibiotics can promote growth of resistance of bacterial pathogens, increase the frequency of adverse reactions of therapy and increase the cost of treatment

Facts and myths about antibiotic therapy

2020 ◽  
Vol 13 (3) ◽  
pp. 289-293
Author(s):  
Bartosz J. Sapilak
Keyword(s):  
Antibiotic Therapy ◽  
Viral Infections ◽  
Clinical Problem ◽  
Symptomatic Treatment ◽  
High Dose ◽  
Cost Of Treatment ◽  
The Right ◽  
The Cost ◽  
Regular Intake ◽  
Selection Of

Resistance to antibiotics is becoming a serious clinical problem. It increases the cost of treatment and is the reason for the failure of therapy. It cannot be eliminated, but the principles of prevention must be respected. First, do not prescribe chemotherapeutics in the therapy of viral infections and symptomatic treatment, after the second care to the selection of a sufficiently high dose, recommend regular intake of the drug and do not shorten the time of therapy. It is also important to choose the right active substance, which should be conditioned by the expected sensitivity of bacteria, the localization of inflammation and the age of the patient. Do not forget about the accompanying therapy, including the ordination of the probiotic and antifungal protection.

Antistaphylococcal activity of carbonic acid extract of hops

2018 ◽  
Vol 22 (2) ◽  
pp. 297-300
Author(s):  
V.V. Nevmerzhitsky ◽  
V.Yu. Ivannik ◽  
V.V. Kazmirchuk ◽  
T.N. Moiseenko ◽  
T.A. Volkov ◽  
...  
Keyword(s):  
Carbon Dioxide ◽  
Antimicrobial Agents ◽  
Carbonic Acid ◽  
Inflammatory Diseases ◽  
Acquired Resistance ◽  
Biologically Active ◽  
Antibacterial Drugs ◽  
Antistaphylococcal Activity ◽  
Prevention And Treatment ◽  
Main Disadvantage

The fight against staphylococcal infection, increasing the effectiveness of methods of prevention and treatment of diseases of staphylococcal etiology is of interest to scientists and practitioners, both in Ukraine and around the world. The urgency of this problem is growing rapidly, as there is a tendency to increase the resistance of not only staphylococci, but also other gram-positive bacteria. The spread of methicillin-resistant staphylococci restricts the choice of antibiotics for the treatment of diseases of staphylococcal etiology. Staphylococcus aureus is the most common and dangerous type, which is one of the main factors of purulent-inflammatory lesions of the skin and mucous membranes. As a result of mutations, pathogenic staphylococci acquired resistance to antibacterial drugs. The main disadvantage of modern antibiotics is their non-selectivity. As a result of mutations, pathogenic staphylococci acquired resistance to antibacterial drugs. The main disadvantage of modern antibiotics is their non-selectivity. One of the unique and promising medicinal plants, which contains a rich complex of biologically active substances (BAS), is common hops (Humulus lupulus L.). The complex of BAS (flavonoids, hormones, vitamins, bitter, phenolic compounds, essential oils) causes anti-inflammatory, bactericidal, hyposensitizing and analgesic action of hops. The purpose of this work is to determine the antistaphylococcal activity of the carbon dioxide extract of hops and to justify the development on its basis of new antimicrobial agents for the prevention and treatment of infectious and purulent-inflammatory diseases. The following methods were used: microbiological (method of diffusion into agar (well method)) and mathematical and statistical. The high antimicrobial activity of the carbon dioxide extract of hops has been established for museum test strains of the genus Staphylococcus. The results of the studies testify to the prospects of further study of the bactericidal properties of the extract of hops carbon dioxide with the aim of creating effective antimicrobial agents on its basis for the prevention and treatment of infectious and purulent-inflammatory diseases of staphylococcal etiology.

OCCURRENCE OF THE RISKS FOR DEVELOPMENT OF RESPIRATORY DISEASES IN CHILDREN EXPOSED TO THE CHEMICAL FACTORS OF THE EXPOSURE OF ALUMINA REFINERY- ASSOCIATED BUSINESS ACTIVITY

2019 ◽  
pp. 42-47 ◽  
Author(s):  
M.A. Zemlianova ◽  
I.V. Tikhonova
Keyword(s):  
Respiratory Tract ◽  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Allergic Inflammation ◽  
Respiratory Morbidity ◽  
Upper Respiratory Tract ◽  
Negative Effects ◽  
Wide Range ◽  
Chemical Factors ◽  
Chronic Lymphoproliferative Diseases

Alumina refineries are among the leading sources of atmospheric air pollution with a wide range of pollutants hazardous to human respiratory organs. It is relevant to study and evaluate the occurrence of the risks for development of respiratory diseases in children living in the area affected by the emission components of an alumina refinery. We assessed air quality of the area under observation and comparison according to monitoring observations, risk of non-carcinogenic effects from the respiratory organs. The content of chemicals in the blood and urine adequate to risk factors was quantified. The structure of individual groups of respiratory diseases was analyzed. The causal relationships of violations of laboratory parameters with an increased content of chemicals in biological media were evaluated. It was found that an aerogenic exposure of chemical pollutants is formed on the territory with the production of metallurgical alumina. It determines the risk for development of respiratory diseases, exceeding an acceptable level up to 49.9 times. In the exposed children, the content of manganese, chromium, nickel, copper, xylenes, formaldehyde and aluminum, fluoride ion in the urine was increased to 4.2 times in relation to the indices in the comparison group. A high level of additional respiratory morbidity(1.8 times) was revealed. Chronic lymphoproliferative diseases of the nasopharynx and inflammatory diseases of the upper respiratory tract (up to 6.6 times more often), inflammatory diseases with a predominance of the mechanism of allergic inflammation ( up to 2.1 times more often)are more often detected in the framework of the respiratory diseases. Negative effects on the part of the respiratory system in the form of activation of antioxidant processes, the development of an inflammatory reaction, local, general and specific sensitization of the respiratory tract were established. It confirms the occurrence of the risks for the development of respiratory diseases in children in the exposure area of the chemical factors of alumina refinery-associated economic activity.

The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases

2020 ◽  
Vol 14 (1) ◽  
pp. 15-31
Author(s):  
Deepak Meshram ◽  
Khushbo Bhardwaj ◽  
Charulata Rathod ◽  
Gail B. Mahady ◽  
Kapil K. Soni
Keyword(s):  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Leukotriene B4 ◽  
Published Data ◽  
Free Text ◽  
Plant Origin ◽  
Medical Subject Headings ◽  
Leukotriene Antagonists ◽  
Mesh Terms ◽  
Mediators Of Inflammation

Background: Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion. Objectives: To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases. Methods: Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study. Results: Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases. Conclusion: The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.

scholarly journals Cost of Management of Diabetes Mellitus: A Pan India Study

2021 ◽  
pp. 097275312199849
Author(s):  
Raghuram Nagarathna ◽  
M Madhava ◽  
Suchitra S Patil ◽  
Amit Singh ◽  
K. Perumal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Urban Areas ◽  
Noncommunicable Disease ◽  
Cost Of Treatment ◽  
Rural And Urban Areas ◽  
Cost Of Disease ◽  
Rural And Urban ◽  
Significant Difference ◽  
The Cost ◽  
Prevalence Of Diabetes Mellitus

Background: Diabetes mellitus is a major noncommunicable disease. While mortality rates are increasing, the costs of managing the disease are also increasing. The all-India average monthly expenditure per person (pppm) is reported to be ₹ 1,098.25, which translates to an annual expenditure of ₹13,179 per person. Purpose: While a number of studies have gone into the aspect of the cost of disease management, we do not find any study which has pan-India reach. We also do not find studies that focus on differences (if any) between rural and urban areas, age or on the basis of gender. We planned to report the cost of illness (COI) in diabetes individuals as compared to others from the data of a pan-India trial. Methods: Government of India commissioned the Indian Yoga Association to study the prevalence of diabetes mellitus in India in 2017. As part of the questionnaire, the cost of treatment was also captured. Data collected from 25 states and union territories were analyzed using the analysis of covriance (ANCOVA) test on SPSS version 21. Results: There was a significant difference ( P < .05) between the average expenses per person per month (pppm) of individuals with self-reported known diabetes (₹1,357.65 pppm) and others (unknown and/or nondiabetes individuals–₹ 999.91 pppm). Similarly, there was a significant difference between rural (₹2,893 pppm) and urban (₹4,162 pppm) participants and between those below (₹1,996 pppm) and above 40 years (₹5,059 pppm) of age. Conclusion: This preliminary report has shown that the COI because of diabetes is significantly higher than others pointing to an urgent need to promote disease-preventive measures.

Are Roundabouts Safe and Economically Viable Replacing Conventional Diamond Interchange Ramp Terminals?

2021 ◽  
pp. 036119812110088
Author(s):  
Boris Claros ◽  
Beau Burdett ◽  
Madhav Chitturi ◽  
Andrea Bill ◽  
David A. Noyce
Keyword(s):  
Empirical Bayes ◽  
Methodological Approach ◽  
Cost Savings ◽  
Weighted Distribution ◽  
Crash Rates ◽  
Design Considerations ◽  
Rate Analysis ◽  
The Cost ◽  
Benefit Cost ◽  
Service Life Cycle

Roundabout implementations at traditional intersections have been shown to be effective at reducing severe crashes. Roundabouts have also been implemented at interchange ramp terminals; however, limited research is available. In this study, 25 roundabout ramp terminal implementations were evaluated. The methodological approach consisted of Empirical Bayes for safety effectiveness and crash cost changes, crash type weighted distribution, crash rate analysis of bypass configuration, and cost of implementation. Roundabouts were effective at reducing fatal and injury crashes when replacing existing interchange diamond ramp terminals: 65% reduction for roundabouts replacing stop-controlled ramp terminals and 41% reduction for roundabouts replacing signal-controlled ramp terminals. Observed crash type weighted distributions are provided to visualize the frequency and location of crashes within roundabout ramp terminals for design considerations. Exit ramp and outside crossroad approaches with right-turn bypass showed significantly lower crash rates than designs without bypass. The crash cost analysis showed that roundabouts replacing diamond ramp terminals yielded crash cost savings of between $95,000 and $253,000 per site per year (69% to 54% decrease in crash costs). Considering crash costs savings only, the cost of implementation should be less than $1.9 million for a roundabout replacing a stop-controlled ramp terminal and less than $5.1 million for a roundabout replacing a signal-controlled ramp terminal to accomplish benefit-cost ratios greater than one for a service life cycle of 20 years. Costs are in 2019 dollars.

scholarly journals Why Do Some Firms Spend So Much on Medical Care? Accounting for Variation

2000 ◽  
Vol 3 (1) ◽  
Author(s):  
Matthew Eichner ◽  
Mark McClellan ◽  
David A. Wise
Keyword(s):  
Health Care ◽  
Health Care Cost ◽  
Health Care Expenditures ◽  
Cost Of Treatment ◽  
Consistent Method ◽  
The Difference ◽  
The Cost ◽  
Cost Differences ◽  
Average Expenditure

We are engaged in a long-term project to analyze the determinants of health care cost differences across firms. An important first step is to summarize the nature of expenditure differences across plans. The goal of this article is to develop methods for identifying and quantifying those factors that account for the wide differences in health care expenditures observed across plans.We consider eight plans that vary in average expenditure for individuals filing claims, from a low of $1,645 to a high of $2,484. We present a statistically consistent method for decomposing the cost differences across plans into component parts based on demographic characteristics of plan participants, the mix of diagnoses for which participants are treated, and the cost of treatment for particular diagnoses. The goal is to quantify the contribution of each of these components to the difference between average cost and the cost in a given firm. The demographic mix of plan enrollees accounts for wide differnces in cost ($649). Perhaps the most noticeable feature of the results is that, after adjusting for demographic mix, the difference in expenditures accounted for by the treatment costs given diagnosis ($807) is almost as wide as the unadjusted range in expenditures ($838). Differences in cost due to the different illnesses that are treated, after adjusting for demographic mix, also accounts for large differences in cost ($626). These components of cost do not move together; for example, demographic mix may decrease expenditure under a particular plan while the diagnosis mix may increase costs.Our hope is that understanding the reasons for cost differences across plans will direct more focused attention to controlling costs. Indeed, this work is intended as an important first step toward that goal.

Sign in / Sign up

Export Citation Format

Share Document